Latest News and Press Releases

Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb. ...

HIGHLIGHTS: Angilak Project: The Angilak Project is host to the Lac 50 Uranium Deposit, which is one of the largest high-grade deposits outside of the Athabasca Basin, with a...

BACKGROUND: ATHA Energy Corp. commenced its 2024 Exploration Program – the Company’s most significant exploration program to date and one of the largest uranium focused exploration programs...

HIGHLIGHTS: The Company has completed its equipment and supply mobilization to its 100%-owned Angilak Project in Nunavut, Canada.Mobilization included the delivery of two X10 Diamond Drills (Tactex...

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer.

2024 EXPLORATION PROGRAM HIGHLIGHTS & UPDATE TO 92 ENERGY TRANSACTION: ATHA begins the Company’s most significant exploration program to date, targeting Canada’s most prospective regions for...

VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (CSE: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA”) is pleased to announce that shareholders (“LUR Shareholders”) of...

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (CSE: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA” or the “Company”), holder of the largest uranium exploration portfolio...

VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (CSE: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA”) is pleased to provide another update on its previously announced...

VANCOUVER, British Columbia, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (CSE: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA” or the “Company”), holder of the largest uranium exploration portfolio...